Gustav Stålhammar1, Viktor T Gill2. 1. St. Erik Eye Hospital, Box 4078, Solna, 171 04 Stockholm, Sweden; Department of Clinical Neuroscience, Division of Eye and Vision, St. Erik Eye Hospital, Karolinska Institutet, Tomtebodavägen 18A, plan 5, 171 77 Stockholm, Sweden. Electronic address: gustav.stalhammar@ki.se. 2. Department of Clinical Neuroscience, Division of Eye and Vision, St. Erik Eye Hospital, Karolinska Institutet, Tomtebodavägen 18A, plan 5, 171 77 Stockholm, Sweden; Department of Pathology, Västmanland Hospital Västerås, Västerås, Sweden.
Abstract
PURPOSE: To examine patient survival in untreated primary uveal melanoma. METHODS: Systematic review and meta-analysis. RESULTS: Seven studies with a total of 19 patients were included. Fifteen patients died from metastases during a median follow-up of > 20 years. When excluding two patients with iris melanoma, fifteen of 17 patients with choroidal or ciliary body melanoma developed metastases. The cumulative disease-specific survival for these 17 patients was 71% at five years, 29% at 10 years, 18% at 15 years and 11% at 30 years. This was significantly worse than the survival in comparison cohorts of both medium-sized and large treated tumors (p < 0.001). CONCLUSIONS: Among the exceedingly rare published patients with untreated primary uveal melanoma, 80-90% have developed metastases and their disease-specific survival seems to be shorter than treated patients. This could indicate that some metastases might be prevented by primary tumor treatment.
PURPOSE: To examine patient survival in untreated primary uveal melanoma. METHODS: Systematic review and meta-analysis. RESULTS: Seven studies with a total of 19 patients were included. Fifteen patients died from metastases during a median follow-up of > 20 years. When excluding two patients with iris melanoma, fifteen of 17 patients with choroidal or ciliary body melanoma developed metastases. The cumulative disease-specific survival for these 17 patients was 71% at five years, 29% at 10 years, 18% at 15 years and 11% at 30 years. This was significantly worse than the survival in comparison cohorts of both medium-sized and large treated tumors (p < 0.001). CONCLUSIONS: Among the exceedingly rare published patients with untreated primary uveal melanoma, 80-90% have developed metastases and their disease-specific survival seems to be shorter than treated patients. This could indicate that some metastases might be prevented by primary tumor treatment.
Authors: Viktor Gill; Christina Herrspiegel; Shiva Sabazade; Maria Fili; Louise Bergman; Bertil Damato; Stefan Seregard; Gustav Stålhammar Journal: Front Med (Lausanne) Date: 2022-06-02